Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Carcinoma, Non-Small-Cell Lung 84Lung Neoplasms 39Carcinoma, Hepatocellular 38Small Cell Lung Carcinoma 26Breast Neoplasms 19Neoplasms 18Cholangiocarcinoma 18Urinary Bladder Neoplasms 17Colorectal Neoplasms 15Triple Negative Breast Neoplasms 13Squamous Cell Carcinoma of Head and Neck 12Pancreatic Neoplasms 10Liver Neoplasms 10Biliary Tract Neoplasms 10Recurrence 9Ovarian Neoplasms 9Neoplasm Metastasis 9Esophageal Neoplasms 8Carcinoma, Renal Cell 8Stomach Neoplasms 7Head and Neck Neoplasms 7Carcinoma, Transitional Cell 7Prostatic Neoplasms 6Melanoma 6Endometrial Neoplasms 6Bile Duct Neoplasms 6Uterine Cervical Neoplasms 5Neoplasms by Site 5Mesothelioma, Malignant 5Adenocarcinoma 5

Interventions

Ipilimumab 5Radiotherapy 4Nivolumab 4Doxorubicin 4CTLA-4 Antigen 4pembrolizumab 3Gemcitabine 3cabozantinib 2brostallicin 2Sunitinib 2Specimen Handling 2Radiation Dose Hypofractionation 2Radiation 2Magnetic Resonance Spectroscopy 2Ifosfamide 2Docetaxel 2Biopsy 23-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 2tremelimumab 1toripalimab 1talimogene laherparepvec 1spartalizumab 1soblidotin 1sintilimab 1saracatinib 1romidepsin 1reolysin 1perifosine 1pazopanib 1fludarabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Histiocytoma, Malignant Fibrous × durvalumab × Clear all
NCT02815995 2025-06-12

Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes

M.D. Anderson Cancer Center

Phase 2 Completed
57 enrolled 18 charts
Sarcoma

Hemangiosarcoma, Leiomyosarcoma, Osteosarcoma, Sarcoma, Synovial, Hemangioendothelioma, Epithelioid, Vascular Neoplasms, Histiocytoma, Malignant Fibrous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡